On 22 Jul 2022, the European Medicines Agency (EMA) has recommended that Rubraca (rucaparib camsylate) should no longer be used as third-line treatment for cancer, as a study that was designed to confirm the benefit of Rubraca failed to do so, and showed that treatment may be associated with a higher risk of death. The study results suggested the patients that were treated with Rubraca lived for an average of 19.4 months, compared with 25.4 months for patients receiving chemotherapy.
Rubraca is a cancer medicine that has been authorised to treat high-grade cancers of the ovary, fallopian tubes (the tubes connecting ovaries to the uterus) and the peritoneum (the membrane lining the abdomen).
EMA recommended, the drug can be used as maintenance treatment in patients whose recurring cancer has cleared (partially or completely) after treatment with platinum-based cancer medicines.
References:
https://www.clinicaltrialsregister.eu/ctr-search/search?query=ARIEL4
https://www.ema.europa.eu/en/news/ema-recommends-restricting-use-cancer-medicine-rubraca
Leave a Reply